Connect with us

Health

Follow-up Sinks Candesartan as Cardioprotection in Breast Cancer – Medscape

The new PRADA findings suggest cardioprotective drugs may not be necessary for all patients during adjuvant breast cancer therapy, the authors say.

Published

on

Article feature image

After a modest early signal of benefit, candesartan cilexetil (Atacand, Cheplapharm) showed no effect on key markers of heart health 2 years after treatment in patients with early-stage breast cancer in the randomized PRADA trial.
The 2015 study was hailed at the time as the largest randomized trial in breast cancer to look at the effects of angiotensin-receptor blockade with candesartan and the -blocker metoprolol, both against placebo, on cardiac dysfunction. The 120 patients received adjuvant…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Andrew and Nicola Forrest’s Mindaroo an investor in COVID nasal spray developed by Hunter researcher Nathan Bartlett – Armidale Express
Article feature image
Plasma therapy boosts survival in Covid patients with blood cancers – The Tribune India